Welcome to our dedicated page for Palatin Tech SEC filings (Ticker: PTNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Palatin Tech's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Palatin Tech's regulatory disclosures and financial reporting.
Palatin Technologies, Inc. reported a net loss of $17.3 million for the year ended June 30, 2025 and management concluded there is substantial doubt about the company’s ability to continue as a going concern. The company sold its Vyleesi product assets and recorded an upfront payment of $9.5 million plus additional consideration, recognizing a $3.13 million gain on the sale and a $2.1179 million gain on eliminated purchase commitments for the fiscal year. Cash and short-term money market deposits included $2,286,603 in money market accounts at June 30, 2025 (compared with $9,089,113 at June 30, 2024). Current liabilities totaled $8,010,030 and certain current assets or balances referenced include $2,564,265. The company continues clinical development across multiple melanocortin receptor (MCR) programs, noting positive topline results reported in 2024–2025 for several programs and projected IND filings for two obesity-focused programs in early 2026. Palatin disclosed extensive financing instruments that may dilute existing shareholders, including convertible preferred stock, options, restricted stock units, and multiple series of warrants outstanding or issuable.
FAQ
What is the current stock price of Palatin Tech (PTNT)?
What is the market cap of Palatin Tech (PTNT)?
